Report
Sumeet Singh
EUR 104.65 For Business Accounts Only

Legend Biotech Follow-on Offering

Legend Biotech, a non-wholly owned subsidiary of Hong Kong-listed GenScript, is planning to raise up to US$250m in its follow-on offering.

The company last raised cash in Dec 2021 in a similar sized deal, which ended up doing very well after a sharp share price correction.

In this note, we will talk about the deal dynamics and run the deal through our ECM framework.
Underlyings
Provider
Aequitas Research
Aequitas Research

Aequitas Research is a leading ECM research firm with a focus on IPOs and placements/follow-on offerings across the Asia Pacific with deal size of over USD100m. 

Since 2015, we have covered 400+ IPOs and 450+ placements with a hit rate of 73% and 65%, respectively. We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic analysis.
 
Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis. We also provide a more quant driven analysis on placement/follow-on offerings.
 
Markets that we cover include:
Hong Kong,
China ADRs,
India,
Japan,
Australia, and
ASEAN.

Analysts
Sumeet Singh

Other Reports on these Companies
Other Reports from Aequitas Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch